Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Breast Cancer Forum

Reply
 
Thread Tools Display Modes
  #1  
Old 07-08-2013, 01:44 PM
Dross Dross is offline
Moderator
 
Join Date: Nov 2006
Posts: 883
Default New target combined with Tamoxifen aids in ER-positive breast cancers

Researchers have identified compounds used in some leukemia treatments that may have an application towards ER positive breast cancer that is unresponsive to traditional treatments.

The discovery was made at the Walter and Eliza Hall Institute. BH3-mimetics were effective in treating aggressive oestrogen receptor-positive breast cancers when combined with the breast cancer drug tamoxifen in preclinical models. Approximately 70 per cent of breast cancers are ER positive.

"Drs Vaillant and Merino looked at the effect of adding BH3-mimetics to the standard hormone treatment, tamoxifen, used for a subtype of ER-positive cancers called luminal B cancers, which had high levels of BCL-2," said Professor Lindeman . "They found that a BH3-mimetic called ABT-199/GDC-0199 improved the effectiveness of hormone therapy by stopping or delaying the growth of these aggressive tumours. In one of the tumour models, the combined treatment caused complete disappearance of the tumour, while standard treatment had only a partial and unsustained benefit."

The new target, BCL-2, is responsible for suppressing a cancer cells desire to apoptose, or kill itself.

Read more: [url]http://www.cell.com/cancer-cell/abstract/S1535-6108(13)00282-1

Last edited by gdpawel : 07-15-2013 at 09:15 AM. Reason: posted full article in forum board
Reply With Quote
  #2  
Old 07-15-2013, 10:34 PM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,354
Default Researchers Identify New Pathway, Enhances Tamoxifen to Tame Aggressive Breast Cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast cancer.

The research, published in the journal EMBO Molecular Medicine, is a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease. This subtype has a poor prognosis because it is notoriously resistant to treatment. In fact, basal-like cancers lack the three most common breast cancer biomarkers – the estrogen receptor, the progesterone receptor, and theHer2/neu receptor – and without these receptors, the usual front-line treatments are not effective.

[url]http://onlinelibrary.wiley.com/doi/10.1002/emmm.201202140/abstract
[url]http://ww5.komen.org/TripleNegativeBreastCancer.html

Until recently, tamoxifen was known primarily for its ability to block estrogen receptors on the outside of cancer cells. However, new studies have suggested that when tamoxifen is given in higher doses, it works through a second mechanism of action independent of the estrogen receptor. This second mechanism was the focus of the Rochester laboratory.

[url]http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682414.html

Led by doctoral student Hsing-Yu Chen and Mark Noble, Ph.D., professor of Biomedical Genetics at URMC, the team studied the molecular mechanism that allows basal-like breast cancer cells to escape the secondary effects of tamoxifen, and discovered that two proteins are critical in this escape. One protein, called c-Cbl, controls the levels of multiple receptors that are critical for cancer cell function. A second protein, Cdc42, can inhibit c-Cbl and is responsible for the tumor’s underlying resistance.

[url]http://www.urmc.rochester.edu/biomedical-genetics/

The team also discovered that targeting Cdc42 – and thus inhibiting the inhibitor - with an experimental drug compound known as ML141 restored c-Cbl’s normal function. Through additional work in animal models and in human cell cultures, the team demonstrated that when ML141 is paired with tamoxifen, it enhances the ability of tamoxifen to induce cancer cell death and suppress the growth of new cancer cells. Neither drug alone had the same effect on basal-like breast cells.

Noble believes there is considerable value to targeting Cdc42, because elevated levels of the protein have been observed in multiple types of cancer. (In this context, scientists are also studying the potential for tamoxifen as a therapy for other cancers.)

[url]http://jcb.rupress.org/content/199/4/567.full

The powerful ML141-tamoxifen drug combination looks like it has two more important features: It selectively targets cancer cells while sparing normal, healthy cells; and it appears to cripple cancer stem cells, the primitive cells responsible for initiating new tumors and for fueling the bulk of the tumor cell population.

“Our work is very exciting because our approach simultaneously addresses two of the most critical challenges in cancer research -- to increase the utility of existing therapies and to discover new vulnerabilities of cancer cells,” said Noble, who also is a leader at UR’s Stem Cell and Regenerative Medicine Institute. “Based on these discoveries, we are already pushing forward with new compounds and with new approaches that might make clinical translation of this discovery much more rapid than would occur with traditional drug-discovery approaches.”

[url]http://www.urmc.rochester.edu/stem-cell/

The National Institutes of Health, Susan G. Komen for the Cure, the U.S. Department of Defense, and the New York State NYSTEM initiative funded the research. Co-authors include Yin Miranda Yang, Ph.D., and Brett Stevens, Ph.D.

Hsing-Yu Chen won a Howard Hughes Medical Institute Award of Excellence in 2012 for a poster presentation on this topic.
__________________
Gregory D. Pawelski
Reply With Quote
Sponsored Links
Advertisement
Reply


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -5. The time now is 12:23 PM.